Familial partial lipodystrophy
Ultimo aggiornamento 22 Ago 2023
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Aggiungi alle fonti preferite su Google
Familial partial lipodystrophy is a rare condition characterised by an abnormal distribution of fatty (adipose) tissue. Adipose tissue is normally found in many parts of the body, including beneath the skin and surrounding the internal organs. It stores fat as a source of energy and also provides cushioning. In people with familial partial lipodystrophy, adipose tissue is lost from the arms, legs, and hips, giving these parts of the body a very muscular appearance. The fat that cannot be stored in the limbs builds up around the face and neck, and inside the abdomen. Excess fat in these areas gives individuals an appearance described as "cushingoid," because it resembles the physical features associated with a hormonal disorder called Cushing disease. This abnormal fat distribution can begin anytime from childhood to adulthood.
Descrizione
Familial partial lipodystrophy is a rare condition characterised by an abnormal distribution of fatty (adipose) tissue. Adipose tissue is normally found in many parts of the body, including beneath the skin and surrounding the internal organs. It stores fat as a source of energy and also provides cushioning. In people with familial partial lipodystrophy, adipose tissue is lost from the arms, legs, and hips, giving these parts of the body a very muscular appearance. The fat that cannot be stored in the limbs builds up around the face and neck, and inside the abdomen. Excess fat in these areas gives individuals an appearance described as "cushingoid," because it resembles the physical features associated with a hormonal disorder called Cushing disease. This abnormal fat distribution can begin anytime from childhood to adulthood.
Abnormal storage of fat in the body can lead to health problems in adulthood. Many people with familial partial lipodystrophy develop insulin resistance, a condition in which the body's tissues cannot adequately respond to insulin, which is a hormone that normally helps to regulate blood sugar (glucose) levels. Insulin resistance may worsen to become a more serious disease called diabetes mellitus. Some people with familial partial lipodystrophy develop acanthosis nigricans, a skin condition related to high levels of insulin in the bloodstream. Acanthosis nigricans causes the skin in body folds and creases to become thick, dark, and velvety.
Most people with familial partial lipodystrophy also have high levels of fats called triglycerides circulating in the bloodstream (hypertriglyceridemia), which can lead to inflammation of the pancreas (pancreatitis). Familial partial lipodystrophy can also cause an abnormal buildup of fats in the liver (hepatic steatosis), which can result in an enlarged liver (hepatomegaly) and abnormal liver function. After puberty, some affected females develop multiple cysts on the ovaries, an increased amount of body hair (hirsutism), and an inability to conceive (infertility), which are likely related to hormonal changes.
Researchers have described at least six forms of familial partial lipodystrophy, which are distinguished by their genetic cause. The most common form of familial partial lipodystrophy is type 2, also called Dunnigan disease. In addition to the signs and symptoms described above, some people with this type of the disorder develop muscle weakness (myopathy), abnormalities of the heart muscle (cardiomyopathy), a form of heart disease called coronary artery disease, and problems with the electrical system that coordinates the heartbeat (the conduction system).
Modelli di ereditarietà
The source lists the following possible inheritance patterns: Autosomal dominant; Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Altri nomi
Dunnigan-Kobberling syndrome
FPL
Kobberling-Dunnigan syndrome
Lipodystrophy, familial partial
Related patient information and medicines

Patient information leaflet
Lipoma
A lipoma is a non-cancerous (benign) fatty lump that usually causes no symptoms or problems. Most lipomas are small and can be left alone. Sometimes a scan or other investigation that is done for other reasons may detect a lipoma inside the body by chance. There is a condition called familial multiple lipoma in which groups of fat cells occur.

Patient information leaflet
Colesterolo alto
Colesterolo è a fat chemical (lipid) that is made in the cells in your body. Many different cells make cholesterol but cells in the liver make about a quarter of the total. Iperlipidemia means too much lipid (particularly cholesterol) in your bloodstream. See the separate leaflet called Hyperlip... In some people a very high level of.

Patient information leaflet
Iperlipidemia
Hyperlipidaemia means a high level of cholesterol or triglycerides in your blood. Hyperlipidaemia is often found when people are overweight or have an unhealthy diet. It can also be the result of drinking too... It can be something that you may have inherited through your family genes (known as primary hyperlipidaemia) and approximately 1 person.

Patient information leaflet
Valutazione del rischio per la salute cardiovascolare
A cardiovascular health risk assessment provides an accurate estimate of your risk of developing cardiovascular disease (eg, angina, heart attack, stroke or peripheral arterial disease) over the following 10 years, and provides an opportunity for you to make any changes that will reduce this risk. Who is a person with familial.

Patient information leaflet
Insulina
Your doctor may prescribe insulin if you have a condition called diabetes. In this condition, your body does not make enough insulin to meet its needs, or if it does, does not use the insulin it makes effectively. ... What are the side-effects of insulin. Apart from hypos (episodes of hypoglycaemia ), insulin has very few side-effects. Lumpiness.

Patient information leaflet
Statine e altri farmaci ipolipemizzanti
Statine work by blocking the action of a certain chemical (enzyme) which is needed to make cholesterol, and by removing some forms of cholesterol from the blood. What are statins. Your doctor will advise if you should take a statin. A statin is usually advised if: You have a high cholesterol level (or high levels of other fats in the blood, called.
Ulteriori letture e riferimenti
- Familial partial lipodystrophy; MedlinePlus, National Library of Medicine.
- Akinci B, von Schnurbein J, Araujo-Vilar D, Wabitsch M, Oral EA. Lipodystrophy Prevalence, "Lipodystrophy-Like Phenotypes," and Diagnostic Challenges. Diabetes. 2024 Jul 1;73(7):1039-1042. doi: 10.2337/dbi24-0018. No abstract available.
- Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial Partial Lipodystrophy (FPLD): Recent Insights. Diabetes Metab Syndr Obes. 2020 May 6;13:1531-1544. doi: 10.2147/DMSO.S206053. eCollection 2020.
- Bidault G, Vatier C, Capeau J, Vigouroux C, Bereziat V. LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations. Biochem Soc Trans. 2011 Dec;39(6):1752-7. doi: 10.1042/BST20110675.
- Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. doi: 10.1210/jc.2016-2466. Epub 2016 Oct 6.
- Donadille B, Janmaat S, Mosbah H, Belalem I, Lamothe S, Nedelcu M, Jannot AS, Christin-Maitre S, Feve B, Vatier C, Vigouroux C. Diagnostic and referral pathways in patients with rare lipodystrophy and insulin-resistance syndromes: key milestones assessed from a national reference center. Orphanet J Rare Dis. 2024 Apr 27;19(1):177. doi: 10.1186/s13023-024-03173-2.
- Fernandez-Pombo A, Diaz-Lopez EJ, Castro AI, Sanchez-Iglesias S, Cobelo-Gomez S, Prado-Morana T, Araujo-Vilar D. Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review. Cells. 2023 Feb 24;12(5):725. doi: 10.3390/cells12050725.
- Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta. 2009 Jun;1791(6):507-13. doi: 10.1016/j.bbalip.2008.12.014. Epub 2009 Jan 7.
- Garg A, Xing C, Agarwal AK, Westfall AK, Tomchick DR, Zhang X, Xing M, Brown RJ. Gain of Function NOTCH3 Variants Cause Familial Partial Lipodystrophy Due to Activation of Senescence Pathways. Diabetes. 2025 Mar 1;74(3):427-438. doi: 10.2337/db24-0624.
- Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011 Nov;96(11):3313-25. doi: 10.1210/jc.2011-1159. Epub 2011 Aug 24.
- Guenantin AC, Briand N, Bidault G, Afonso P, Bereziat V, Vatier C, Lascols O, Caron-Debarle M, Capeau J, Vigouroux C. Nuclear envelope-related lipodystrophies. Semin Cell Dev Biol. 2014 May;29:148-57. doi: 10.1016/j.semcdb.2013.12.015. Epub 2013 Dec 30.
- Hussain I, Garg A. Lipodystrophy Syndromes. Endocrinol Metab Clin North Am. 2016 Dec;45(4):783-797. doi: 10.1016/j.ecl.2016.06.012. Epub 2016 Oct 6.
- Maung JN, Oral EA, MacDougald OA. Lamin A/C in health, laminopathies, and familial partial lipodystrophy 2. Trends Endocrinol Metab. 2026 Sep;37(9):826-852. doi: 10.1016/j.tem.2026.01.010. Epub 2026 Mar 17.
- Rutkowska L, Salachna D, Lewandowski K, Lewinski A, Gach A. Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3. Diagnostics (Basel). 2022 Apr 30;12(5):1122. doi: 10.3390/diagnostics12051122.
- Simha V, LoPiccolo MK, Platt A, Brown RJ, Johnson X, Carere DA, Donnelly C, Snyder MT, Xing C, Mathews TP, Gopal P, Ward SC, Tomchick DR, Agarwal AK, DeBerardinis RJ, Garg A. A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia. J Clin Invest. 2025 Nov 4;136(1):e198888. doi: 10.1172/JCI198888. eCollection 2026 Jan 2.
- Valerio CM, Viola LF, Guidorizzi NR, Lima JG, Godoy-Matos AF, Hohl A, Trujilho FR, Dantas JR, de Melo Campos JTA, Zajdenverg L, Muniz RBG, Moreira RO, Fernandes VO, Foss-Freitas MC, Montenegro R Jr. Brazilian expert consensus on the diagnosis, classification, screening for complications and treatment of familial partial lipodystrophy. Diabetol Metab Syndr. 2025 Jun 2;17(1):186. doi: 10.1186/s13098-025-01733-5.
- Vigouroux C, Guenantin AC, Vatier C, Capel E, Le Dour C, Afonso P, Bidault G, Bereziat V, Lascols O, Capeau J, Briand N, Jeru I. Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus. 2018 Jan 1;9(1):235-248. doi: 10.1080/19491034.2018.1456217.
Partecipa alla conversazione
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.

Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.